PREDNISONE TABLETS

Myeloid Malignancies

Prelude TherapeuticsSmall moleculePhase 3Active

BB

70/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 57/ 100
Competitive Position: 95/ 100

Competitive context

12 Active assets in the Myeloid Malignancies cohort.

Asset / Sponsor	Phase	Rating
Cyclophosphamide Prelude Therapeutics	Phase 3	BB
Inno-206 Prelude Therapeutics	Phase 3	BB
FILGRASTIM Franziska Wachter	Phase 2	BB
Fludarabine First Affiliated Hospital of Zhejiang University	Phase 3	BB
Evomela First Affiliated Hospital of Zhejiang University	Phase 3	BB

View all 14 →

Same molecule, other indications

PREDNISONE TABLETS is also rated in:

Recurrent Adult T-cell Leukemia/LymphomaDormant

BBB

Indicative ·

76 / 100

diffuse large B-cell lymphomaDormant

BBB

Indicative ·

74 / 100

metastatic prostate carcinomaDormant

BBB

Indicative ·

74 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.